Are you M S Hussain?

Claim your profile

Publications (3)6.78 Total impact

  • [show abstract] [hide abstract]
    ABSTRACT: Accurate estimation of an intracranial vessel size is crucial during a diagnostic or therapeutic angiography procedure. The use of 1 or 2 external markers of known size is previously proposed to manually estimate the magnification factor (MF) of an intracranial vessel. The authors evaluated the use of different external marker techniques commonly used during angiographic measurements. Forty-three intracranial vessels in 17 patients were measured using 1-and 2-marker techniques. To obtain the MF, 2 metallic markers were attached to the frontal-temporal regions. The MFs for the targeted vessels were obtained from the x-ray films by measuring the image sizes of the markers and their positions with respect to the target vessel. Using a phantom, the errors resulted from (a) linear interpolation of MFs, (b) linear interpolation of inverse MFs, and (c) using the MFs of 1 marker, which were 1.23% to 2.23%, 0.8% to 1.55%, and 3.85% to 14.62%, respectively. A similar trend was observed for the measurement of cerebral arteries. The use of 2 markers can result in a more accurate estimation of the vessel size. The use of only 1 external marker can lead to substantial error based on the location of the target vessel. Optimizing image acquisition is also crucial for accurate determination of vessel size.
    Journal of Neuroimaging 11/2005; 15(4):356-61. · 1.41 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: To determine the rates of intracranial hemorrhages associated with GP IIb/IIIa inhibitors in routine practice. Rates of intracranial hemorrhages (ICH) among patients treated with platelet glycoprotein (GP) IIb/IIIa inhibitors for coronary interventions and acute coronary syndromes have been studied within clinical trials but not in routine practice. We evaluated the rates of ICH in routine practice in United States (US) using national estimates of rates, in-hospital outcomes, and mortality obtained from National Hospital Discharge Survey. There were 367 294 patients aged 18 years or greater who were treated with platelet GP IIb/IIIa inhibitors between 2000 and 2002 in United States. ICH was observed in 479 (0.13%) of the 367,294 patients with a 100% associated mortality. ICHs related to GP IIb/IIIa inhibitors comprised 0.12% of the total number of ICHs (n = 411 621) observed in United States between 2000 and 2002. ICH related to platelet GPIIb/IIIa inhibitors is uncommon but associated with high mortality.
    Cardiovascular Drugs and Therapy 11/2005; 19(5):371-3. · 2.67 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Several developments in endovascular technology have greatly expanded the application of these techniques to treat extra- and intracranial cerebrovascular diseases. This review explores the indications, techniques, and clinical results for endovascular treatment of ischemic stroke and intracranial stenoses, aneurysms, and arteriovenous malformations.
    Journal of Endovascular Therapy 01/2005; 11 Suppl 2:II32-42. · 2.70 Impact Factor